BenevolentAI Ltd (BenevolentAI) is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases. The company’s drug programs include BEN2293 (atopic dermatitis), BEN8744 (ulcerative colitis), BEN9160 (amyotrophic lateral sclerosis), glioblastoma multiforme, inflammatory bowel disease, CNS diseases, antiviral, nonalcoholic steatohepatitis (NASH), oncology, Parkinson’s disease, chronic kidney disease, idiopathic pulmonary fibrosis and others. BenevolentAI’s platform enables scientists to design and develop new treatments for patients, using a large amount of extracted and deduced biomedical information. The company operates in the UK and the US. BenevolentAI is headquartered in London, England, the UK.

Gain a 360-degree view of BenevolentAI Ltd and make more informed decisions for your business Gain a 360-degree view of BenevolentAI Ltd and make more informed decisions for your business Contact Us
Headquarters United Kingdom

Address 4-8 Maple Street, London, England, W1T5HD


No of Employees 248

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange BAI (AMS)

Revenue (2022) $9.1M -30.6% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ 61.4% (2022 vs 2021)

Market Cap* $104.7M

Net Profit Margin (2022) XYZ 44.4% (2022 vs 2021)

   

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Contact Us

BenevolentAI Ltd premium industry data and analytics

30+

Pipeline Drugs

Identify which of BenevolentAI Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

8

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for BenevolentAI Ltd’s relevant decision makers and contact details.

7

Catalyst Calendar

Proactively evaluate BenevolentAI Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

5

Clinical Trials

Determine BenevolentAI Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products Services
BEN2293 (Atopic Dermatitis) Data foundations
BEN8744 (Ulcerative Colitis) Target identification
BEN9160 (Amyotrophic Lateral Sclerosis) Drug programmes
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand BenevolentAI Ltd portfolio and identify potential areas for collaboration Understand BenevolentAI Ltd portfolio and identify potential areas for collaboration Contact Us

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In September, the company signed a collaboration with Merck to enable Merck to leverage the company’s powerful end-to-end AI platform.
2022 Contracts/Agreements In October, the company and AstraZeneca partnered to integrates AstraZeneca’s data into its biomedical Knowledge Graph to rapidly normalise and contextualise a diverse range of external and internal data from numerous sources.
2022 Acquisitions/Mergers/Takeovers In April, the company merged with Odyssey Acquisition SA.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Contact Us
Image for loader

Competitor Comparison

Key Parameters BenevolentAI Ltd Acacia Pharma Group Ltd 4D Pharma Plc Aria Pharmaceuticals Inc Cresset BioMolecular Discovery Ltd
Headquarters United Kingdom United Kingdom United Kingdom United States of America United Kingdom
City London Cheshire Leeds Palo Alto Litlington
State/Province England England England California Cambridgeshire
No. of Employees 248 74 95 - 46
Entity Type Public Private Private Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Contact Us
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Contact Us
Executives
Name Position Board Since Age
Francois Nader Chairman Executive Board 2023 -
Joerg Moeller, MD, PhD Director; Chief Executive Officer Executive Board 2024 -
Ivan Griffin Co-Founder; Chief Operating Officer Executive Board 2014 -
Anna Fullerton-Batten Chief People Officer Executive Board - -
James Malone Chief Technology Officer Senior Management 2024 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into BenevolentAI Ltd key executives to enhance your sales strategy Gain insight into BenevolentAI Ltd key executives to enhance your sales strategy Contact Us
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward